(Q33893393)

29 July 2017

1 reference

title

New therapies for systemic lupus erythematosus. (English)

1 reference

systemic lupus erythematosus

29 July 2017

0 references

author name string

Strand V

series ordinal

1

1 reference

29 July 2017

1 May 2000

1 reference

Rheumatic Diseases Clinics of North America

29 July 2017

1 reference

29 July 2017

26

1 reference

29 July 2017

2

1 reference

29 July 2017

389-406, viii

1 reference

Immunoregulatory circuits and potential treatment of connective tissue diseases

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970145-9

7 January 2021

Interleukin-10 (IL-10) secretion in systemic lupus erythematosus and rheumatoid arthritis: IL-10-dependent CD4+CD45RO+ T cell-B cell antibody synthesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970145-9

7 January 2021

Bromocriptine in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970145-9

7 January 2021

The effect of a selective estrogen receptor modulator on the progression of spontaneous autoimmune disease in MRL lpr/lpr mice

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970145-9

7 January 2021

Bromocriptine immunomodulation of experimental SLE and primary antiphospholipid syndrome via induction of nonspecific T suppressor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970145-9

7 January 2021

Successful mycophenolate mofetil treatment of glomerular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970145-9

7 January 2021

Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970145-9

7 January 2021

A pilot study of 2-chloro-2'-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970145-9

7 January 2021

Recombinant human Dnase I (rhDNase) in patients with lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970145-9

7 January 2021

Dehydroepiandrosterone (DHEA) and systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970145-9

7 January 2021

Differential effects of estrogen and prolactin on autoimmune disease in the NZB/NZW F1 mouse model of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970145-9

7 January 2021

Gene therapy in autoimmune diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970145-9

7 January 2021

Autoantibodies to the protein core of vascular basement membrane heparan sulfate proteoglycan in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970145-9

7 January 2021

Treatment of murine lupus with CTLA4Ig

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970145-9

7 January 2021

Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970145-9

7 January 2021

Binding of a monoclonal anti-DNA autoantibody to identical protein(s) present at the surface of several human cell types involved in lupus pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970145-9

7 January 2021

Immunospecific reduction of antioligonucleotide antibody-forming cells with a tetrakis-oligonucleotide conjugate (LJP 394), a therapeutic candidate for the treatment of lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970145-9

7 January 2021

The role of the CD28 receptor during T cell responses to antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970145-9

7 January 2021

Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970145-9

7 January 2021

Complement-specific antibodies: Designing novel anti-inflammatories

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970145-9

7 January 2021

Safety of hormonal replacement therapy in postmenopausal patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970145-9

7 January 2021

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970145-9

7 January 2021

Spontaneous autoimmune disease in (NZB x NZW)F1 mice is ameliorated by treatment with methimazole

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970145-9

7 January 2021

Autologous peripheral blood stem and progenitor (CD34+) cell transplantation for systemic lupus erythematosus complicated by Evans syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970145-9

7 January 2021

Oral contraceptives and systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970145-9

7 January 2021

Modulation of disease activity in murine systemic lupus erythematosus by cytokine gene delivery

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970145-9

7 January 2021

Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970145-9

7 January 2021

Expression of CD28, CTLA4, CD80, and CD86 molecules in patients with autoimmune rheumatic diseases: implications for immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970145-9

7 January 2021

New methods of treatment in an experimental murine model of systemic lupus erythematosus induced by idiotypic manipulation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970145-9

7 January 2021

Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970145-9

7 January 2021

Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970145-9

7 January 2021

An open study of dehydroepiandrosterone in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970145-9

7 January 2021

DNAse treatment does not improve the survival of lupus prone (NZB x NZW)F1 mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970145-9

7 January 2021

Prolactin: a stimulator of disease activity in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970145-9

7 January 2021

Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970145-9

7 January 2021

Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritides

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970145-9

7 January 2021

Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970145-9

7 January 2021

10.1016/S0889-857X(05)70145-9

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10768219